GR
Therapeutic Areas
CEL-SCI Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Multikine (Leukocyte Interleukin, Injection) | Advanced Primary Head and Neck Cancer | Phase 3 |
| LEAPS Technology | Rheumatoid Arthritis | Pre-clinical |
Leadership Team at CEL-SCI
ET
Eyal Talor, Ph.D.
Chief Scientific Officer
PB
Patricia B. Prichep
Chief Financial and Operations Officer
JC
John Cipriano
Senior Vice President of Regulatory Affairs
W"
William "Brooke" Jones
Quality Assurance Advisor
GS
Giovanni Selvaggi, MD
Acting Chief Medical Officer